Skip to content

Clinical Study for the Impact of Bio-absorbable Felt (NEOVEIL®) With Fibrin Sealant on Removal of Drainage Tube After Minimally Invasive Gastrectomy for Gastric Cancer

Clinical Study for the Impact of Bio-absorbable Felt (NEOVEIL®) With Fibrin Sealant on Removal of Drainage Tube After Minimally Invasive Gastrectomy for Gastric Cancer: Multicenter Prospective Randomized Comparison Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01742806
Enrollment
120
Registered
2012-12-05
Start date
2012-10-31
Completion date
2013-06-30
Last updated
2012-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Keywords

Gastric cancer, Minimally invasive surgery, Distal gastrectomy, Bio-absorbable Felt

Brief summary

This study is to evaluate if Bio-absorbable Felt(NEOVEIL®) makes the amount of exudate reduce and shortens time until drain removal after minimally invasive surgery for early gastric cancer.

Detailed description

We investigate the effect on drainage amount of Bio-absorbable Felt(NEOVEIL®) after D1+b or D2 lymphadenectomy with distal gastrectomy for early gastric cancer. This study is an randomised controlled trial undertaken in 7 centers in South Korea. Patients with stage I-II gastric cancer who is going to have curative distal gastrectomy with D1+b or D2 lymphadenectomy are randomly assigned to use bio-absorbable felt(NEOVEIL®) or not to use it. Block randomisation will be done by a central interactive computerised system, stratified by center.

Interventions

DEVICEbio-absorbable felt(NEOVEIL®)

To cover bio-absorbable felt over the lymphadenectomy area (hepatoduodenal ligament, #5 and 12/gastroduodenal artery, #6/ pancreas head /suprapancreatic area, #7,8 and 9)

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* histologic confirmed gastric adenocarcinoma * Patients who underwent laparoscopic distal gastrectomy. * preoperative clinical stage I diagnosed with esophagogastroduodenoscopy,endoscopic ultrasonography and computerized tomography. * patients who underwent more than D1+b lymphadenectomy

Exclusion criteria

* Vulnerable participants (pregnant women, under 20 year old, and so on) * liver or renal disease (Ex. liver cirrhosis, end stage renal disease) * Transfusion is needed preoperatively or postoperatively due to bleeding * Preoperative or intraoperative evaluation confirm ascites. * Patients who use anticoagulant preoperatively or postoperatively

Design outcomes

Primary

MeasureTime frameDescription
Time to drain removaltwo weeksDaily amount of exudate is less than 100cc during consecutive 2 days. There is no evidence of anastomotic leakage, intra-abdominal abscess or bleeding.

Secondary

MeasureTime frameDescription
total amount of exudate drainagetwo weeksTotal amount of exudate after surgery is recorded.

Other

MeasureTime frameDescription
Time to discharge after surgery and postoperative complicationup to 30days after randomizationTime to discharge after surgery and postoperative complication are recorded

Countries

South Korea

Contacts

Primary ContactWOO JIN HYUNG, M.D. Ph.D.
wjhyung@yuhs.ac82-2-2228-2129

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026